Integra LifeSciences Holdings Co. (NASDAQ:IART) Stake Decreased by Xponance Inc.

Xponance Inc. lessened its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,148 shares of the life sciences company’s stock after selling 367 shares during the period. Xponance Inc.’s holdings in Integra LifeSciences were worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Swiss National Bank raised its holdings in shares of Integra LifeSciences by 0.9% during the third quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock valued at $6,187,000 after buying an additional 1,500 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Integra LifeSciences during the third quarter valued at approximately $43,034,000. Cardinal Capital Management increased its stake in shares of Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after acquiring an additional 347 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences during the third quarter valued at approximately $25,443,000. Finally, Vanguard Group Inc. increased its stake in shares of Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock valued at $273,435,000 after acquiring an additional 72,294 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 0.2 %

NASDAQ IART opened at $28.34 on Friday. Integra LifeSciences Holdings Co. has a twelve month low of $27.18 and a twelve month high of $56.21. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 34.14, a PEG ratio of 0.86 and a beta of 1.12. The firm’s 50 day moving average price is $35.34 and its two-hundred day moving average price is $38.76.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. During the same quarter in the previous year, the firm posted $0.94 earnings per share. The company’s revenue for the quarter was down .3% on a year-over-year basis. Equities analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a research note on Wednesday, April 3rd. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. Finally, JMP Securities decreased their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.